Topanga Partners Profile
Topanga Partners is a private equity firm based in Pittsburgh, PA that invests in early stage companies primarily in the life sciences and technology sectors. In addition to passive venture investments, we also consider M&A transactions, recapitalizations, and Alpha/Beta stage investments. Depending on size and stage, we can also provide operational and strategic services to mitigate risk to investors, drive capital efficiencies, and build enterprise value.
David Gormley, Managing Partner
David is the Managing Partner of Topanga and handles its day to day operations and portfolio companies. He has more than 30 years of experience in corporate, investment and private banking, brokerage, and funds management. David was born and raised in Pittsburgh, and graduated from Columbia University with a degree in Economics. He spent his early years on Wall Street in several progressive operational roles, and earned additional diplomas from American Institute of Banking and New York Institute of Finance. David was then recruited by Citibank where spent 23 years in senior management positions for the firm in New York, Europe, and Asia. During that period, he also earned a certificate from Stanford Graduate School of Business and completed Citibank’s Senior Risk Seminar in Switzerland. Subsequently, David successfully established a listed trading company on the Hong Kong Stock Exchange and later was recruited by Franklin Templeton to build and run a subsidiary in Asia.
JOHN HATHAWAY, Managing Director
John manages the General Partner for Topanga and is the founder of Pittsburgh based private equity firm Primerock Capital. Primerock invests its own capital in various private equity sectors, and through its affiliates manages multiple private funds and companies. John has more than 25 years of experience in asset management, capital structure and formation, mergers and acquisitions, sales and marketing, and finance. Early in his career, he personally managed over $1 Billion of retail client assets for several wall street banks. Subsequently on the private equity side, John has led hundreds of transactions, including in the real estate, manufacturing, technology, and financial sectors. He serves on the boards of multiple privately held companies, and maintains a large network of partners and co-investors. John holds a degree in Economics from the University of Pennsylvania.
About Our Portfolio Companies
InClinica guides companies through early stage FDA clinical trials and also owns equity stakes in early stage life sciences companies, including positions in both SkinJect and Periovance..
Postamo is an online platform that makes it fast and easy for real estate agents to connect with home sellers and buyers through Facebook, Twitter, and LinkedIn. Postamo gives agents the opportunity to advertise their local expertise, listings, brand and more so they can grow their business.
Health eTools is an electronic health records (EHR) system created specifically for school nurses using Human Centered Designed. Serving more than 700 schools across the country, Health eTools works in conjunction with a school district’s existing Student Information System to help school nurses confidentially track, manage and report on the health of their student population.
Nestigator is an award winning online platform used by over 200,000 real estate agents nationwide. Nestigator makes Home Buying and Selling easier by connecting consumers with local real estate experts ready to assist on demand.
sharp edge labs
Sharp Edge is bringing a new class of targeted biosensors to drug discovery and trafficking biology. Fluorogenic Activating Modules (or FAMs) provide a more accurate and detailed detection method for cellular trafficking that is amendable to high-throughput screening and more detailed follow-up.
Periovance’s PSR system is a patented, non-surgical treatment and product for periodontal disease that is currently in FDA Trials.
SkinJect’s patch is a patented, non-surgical treatment for basal cell carcinoma that is in the pre-clinical stage with the FDA.